Next Article in Journal
Skull Bone Regeneration Using Chitosan–Siloxane Porous Hybrids—Long-Term Implantation
Next Article in Special Issue
Simultaneous Determination of Five Cytochrome P450 Probe Substrates and Their Metabolites and Organic Anion Transporting Polypeptide Probe Substrate in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry
Previous Article in Journal
Twin Screw Granulation: Effects of Properties of Primary Powders
Previous Article in Special Issue
Qualification and Application of a Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometric Method for the Determination of Adalimumab in Rat Plasma
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessArticle
Pharmaceutics 2018, 10(2), 69; https://doi.org/10.3390/pharmaceutics10020069

A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry Disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse

1
College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Daejeon 34134, Korea
2
Research Institute for Future Medicine, Samsung Medical Center, Seoul 135-710, Korea
3
Green Cross Research Center, Green Cross, Gyeonggi-do 446-850, Korea
4
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
*
Authors to whom correspondence should be addressed.
Received: 16 April 2018 / Revised: 2 June 2018 / Accepted: 4 June 2018 / Published: 7 June 2018
(This article belongs to the Special Issue Drug Metabolism, Pharmacokinetics and Bioanalysis)
View Full-Text   |   Download PDF [4411 KB, uploaded 7 June 2018]   |  

Abstract

Fabry disease is a rare lysosomal storage disorder resulting from the lack of α-Gal A gene activity. Globotriaosylceramide (GB3, ceramide trihexoside) is a novel endogenous biomarker which predicts the incidence of Fabry disease. At the early stage efficacy/biomarker study, a rapid method to determine this biomarker in plasma and in all relevant tissues related to this disease simultaneously is required. However, the limited sample volume, as well as the various levels of GB3 in different matrices makes the GB3 quantitation very challenging. Hereby we developed a rapid method to identify GB3 in mouse plasma and various tissues. Preliminary stability tests were also performed in three different conditions: short-term, freeze-thaw, long-term. The calibration curve was well fitted over the concentration range of 0.042–10 μg/mL for GB3 in plasma and 0.082–20 μg/g for GB3 in various tissues. This method was successfully applied for the comparison of GB3 levels in Fabry model mice (B6;129-Glatm1Kul/J), which has not been performed previously to the best of our knowledge. View Full-Text
Keywords: GB3; Fabry disease; LC-QTOF-MS/MS; B6;129-Glatm1Kul/J GB3; Fabry disease; LC-QTOF-MS/MS; B6;129-Glatm1Kul/J
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Shin, S.-H.; Park, M.-H.; Byeon, J.-J.; Lee, B.; Park, Y.; Ko, A.-R.; Seong, M.-R.; Lee, S.; Kim, M.R.; Seo, J.; Jung, M.E.; Jin, D.-K.; Shin, Y.G. A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry Disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse. Pharmaceutics 2018, 10, 69.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top